Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.84 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22421741 | 1.00 | BCL6 (1.00) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL21774734 | 1.00 | BCL6 (1.00) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284531 | 1.00 | BCL6 (1.00) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL21774726 | 1.00 | BCL6 (1.00) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL29508785 | 1.00 | BCL6 (1.00) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20267381 | 1.00 | BCL6 (1.00) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284190 | 0.95 | BCL6 (0.90) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284231 | 0.95 | BCL6 (0.90) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20267635 | 0.95 | BCL6 (0.90) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL21787706 | 0.94 | BCL6 (0.89) | BCL6MELKNCOR2CHRM4BCL6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| US-20220281931-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | claimed |
| US-20210330672-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | TEQLA THERAPEUTICS, INC. | 2021-10-28 | — | — | US | claimed |
| WO-2021102283-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | WO | claimed |
| EP-3728232-B1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-08-30 | — | — | EP | disclosed |
| EP-4061834-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-20220281931-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11192880-B2 | Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-12-07 | — | — | US | disclosed |
| US-20210330672-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | TEQLA THERAPEUTICS, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210330672-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | TEQLA THERAPEUTICS, INC. | 2021-10-28 | — | — | US | disclosed |
| WO-2021102283-A1 | CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| EP-3820500-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | Teqla Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-20200325119-A1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-15 | — | — | US | disclosed |
| US-20200308147-A1 | NOVEL DEUTERATED COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-10-01 | — | — | US | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330672-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 438/4885NCOR2 697/4885 |
| US-11192880-B2 | Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 401/4885NCOR2 65/4885 |
| US-20200308147-A1 | NOVEL DEUTERATED COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 339/4885NCOR2 76/4885 |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 393/4885NCOR2 101/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 366/4885NCOR2 90/4885 |
| US-20200325119-A1 | NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 468/4885NCOR2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.